Survival is not the only valuable end point in melanoma screening
- PMID: 22336950
- PMCID: PMC4575123
- DOI: 10.1038/jid.2012.3
Survival is not the only valuable end point in melanoma screening
References
-
- ACS Cancer Facts & Figures. 2011 http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/docume....
-
- Agnese DM, Abdessalam SF, Burak WE, Jr, et al. Cost-effectiveness of sentinel lymph node biopsy in thin melanomas. Surgery. 2003;134(4):542–7. discussion 547–8. - PubMed
-
- Aitken JF, Elwood JM, Lowe JB, et al. A randomised trial of population screening for melanoma. J Med Screen. 2002;9:33–37. - PubMed
-
- Aitken JF, Janda M, Elwood M, et al. Clinical outcomes from skin screening clinics within a community-based melanoma screening program. J Am Acad Dermatol. 2006;54(1):105–14. - PubMed
-
- Albert LS, Rhodes AR, Sober AJ. Dysplastic melanocytic nevi and cutaneous melanoma: markers of increased melanoma risk for affected persons and blood relatives. J Am Acad Dermatol. 1990;22(1):69–75. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
